Table 1.
Hela | SiHa | C-33A | |
---|---|---|---|
NKG2D | |||
Basal | 2235 | 2235 | 2235 |
Without HO-1 Inhibitor | 1690 | 1830 | 2110 |
SnPP | 2145* | 2050* | 2198 |
ZnPP | 2189* | 2012* | 2241 |
NKp30 | |||
Basal | 2127 | 2127 | 2127 |
Without HO-1 Inhibitor | 888 | 1609 | 1658 |
SnPP* | 1848 | 1949 | 2087 |
ZnPP* | 1929 | 1893 | 1989 |
NKp44 | |||
Basal | 2025 | 2025 | 2025 |
Without HO-1 Inhibitor | 1684 | 1801 | 2090 |
SnPP | 2110* | 2087* | 2089 |
ZnPP | 1989* | 2046* | 2105 |
NKp46 | |||
Basal | 1900 | 1900 | 1900 |
Without HO-1 Inhibitor | 1500 | 1588 | 1610 |
SnPP* | 1925 | 2043 | 1892 |
ZnPP* | 1875 | 1984 | 1931 |
CCC HeLa, SiHa, and C-33A were pre-treated with SnPP or ZnPP HO-1 inhibitors. Afterward, transwell assays were performed between NK-92 cells and HeLa, SiHa, and C-33A. Subsequently, the geometric Mean fluorescence intensity (MIF) of NKG2D, NKp30, NKp44, and NKp46 were determined. The Standard deviation (SD) of MIF in all groups did not exceed 135. *P <0.05 SnPP- or ZnPP-treated CCC vs. HeLa, SiHa, and C-33A without treatment.